Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant
Status:
Unknown status
Trial end date:
2019-04-30
Target enrollment:
Participant gender:
Summary
To describe how Nulojix (belatacept) is used and to determine how often Post-Transplant
Lymphoproliferative Disorder (PTLD), Central Nervous System (CNS) PTLD and Progressive
Multifocal Leukoencephalopathy (PML), rare and serious complications of transplant treatment,
occur in patients taking Nulojix (belatacept) in a real-world setting.